Psoriatic Arthritis

Methotrexate plus leflunomide a treatment option for psoriatic arthritis

Journal

The Lancet Rheumatology

18 March, 2022 19:53

Explaining arthropathy development through IL-4 and IL-13 blockade

Presented By

Dr Charlie Bridgewood, University of Leeds, UK

Conference

PFGC 2021

3 February, 2022 10:51

Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion

Presented By

Dr Ali Al-Janabi, University of Manchester, UK

Conference

PFGC 2021

2 February, 2022 15:22

Selective IL-23 inhibition normalises gene expression in active PsA

Presented By

Ms Michelle Miron

Trial

Phase 3, DISCOVER-1&-2

Conference

PFGC 2021

2 February, 2022 13:48

Selective IL-23 inhibition: a new option in active PsA

Presented By

Prof. Andrew Östör, Monash University, Australia

Trial

Phase 3, KEEPsAKE 1, KEEPsAKE 2

Conference

ACR 2021

14 January, 2022 10:52

Ustekinumab: highly efficacious in PSA independent of methotrexate

Presented By

Dr Michaela Köhm, Goethe-University Frankfurt, Germany

Conference

ACR 2021

14 January, 2022 10:48

B-cell depleting medication increases COVID-19 breakthrough infection outcome risk

Presented By

Prof. Jean Liew, Boston University, MA, USA

Conference

ACR 2021

14 January, 2022 10:45

PFGC 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

PFGC 2021

22 December, 2021 08:12

Support for therapeutic drug monitoring with infliximab maintenance therapy

Journal

JAMA

21 December, 2021 17:19

Guselkumab boosts response in resistant psoriatic arthritis

Journal

Annals of the Rheumatic Diseases

30 November, 2021 21:21

ACR 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ACR 2021

22 November, 2021 16:18

B-cell-targeted therapy linked with severe COVID-19 among patients with arthritis

Journal

Annals of the Rheumatic Diseases

8 October, 2021 16:02

Live varicella-zoster vaccine safe, effective with TNF inhibitors

Journal

Annals of Internal Medicine

29 September, 2021 23:18

Could steroid treatment speed recovery from infliximab-induced liver injury?

Journal

Journal of Hepatology

28 September, 2021 17:12

Oral CBD fails to relieve pain from hand osteoarthritis, psoriatic arthritis, but questions linger

Journal

Pain

20 September, 2021 19:15

Unresolved needs for patients with PsA despite growing therapeutic options

Conference

WPPAC 2021

17 September, 2021 13:46

Bridging the gap between patients and access to psoriasis specialists

Presented By

Dr Silvia Fernandez Barrio, AEPSO, Argentina

Conference

WPPAC 2021

17 September, 2021 13:42

Psoriasis and PsA in transgender adults on hormone therapy

Presented By

Ms Julia Gao, Fenway Health, MA, USA

Conference

WPPAC 2021

17 September, 2021 13:41

Active PsA: Biomarkers distinguish radiographic progressors from non-progressors

Trial

Phase 3, SPIRIT-P1

Conference

WPPAC 2021

17 September, 2021 13:37

Axial involvement is critical in psoriatic arthritis

Presented By

Dr Elena Gubar, Nasonova Research Institute of Rheumatology, Russia

Conference

WPPAC 2021

17 September, 2021 13:34

Vaccination feasible in people with psoriatic disease

Presented By

Prof. Ulrich Mrowietz, University Medical Centre Schleswig-Holstein, Germany

Conference

WPPAC 2021

17 September, 2021 12:30

Pan-European guidelines for the treatment of psoriasis and comorbid conditions

Presented By

Prof. Alexander Nast, Charité Universitätsmedizin Berlin, Germany

Conference

WPPAC 2021

17 September, 2021 12:09

Psoriatic arthritis: Guidelines and best practice

Trial

Phase 3, BE ACTIVE, PATERA

Conference

WPPAC 2021

17 September, 2021 11:19

Patients with PsA have a higher cardiovascular risk

Presented By

Dr Natalia Guajardo-Jauregui, Autonomous University of Nuevo León, Mexico

Conference

WPPAC 2021

17 September, 2021 11:16

Severe flares of rheumatic, musculoskeletal disease rare after COVID-19 vaccination

Journal

Arthritis and Rheumatology

6 September, 2021 16:11

Efficacy and safety of secukinumab in juvenile idiopathic arthritis

Presented By

Dr Nicola Ruperto, IRCCS Istituto G. Gaslini, Italy

Trial

Phase 3, JUNIPERA

Conference

EULAR 2021

2 August, 2021 23:33

Guselkumab efficacious in PsA patients with inadequate response to TNF inhibition

Presented By

Dr Laura Coates , University of Oxford, UK

Trial

Phase 3, COSMOS

Conference

EULAR 2021

2 August, 2021 22:06

Faecal microbiota transplantation not effective in active peripheral PsA

Presented By

Dr Maja Skov Kragsnaes , University of Southern Denmark, Denmark

Trial

FLORA

Conference

EULAR 2021

2 August, 2021 21:08

Risankizumab meets primary and ranked secondary endpoints in PsA

Presented By

Prof. Andrew Östör, Monash University, Australia

Trial

Phase 3, KEEPsAKE 2

Conference

EULAR 2021

2 August, 2021 20:10

Prognostic factors for minimal disease activity in early psoriatic arthritis revealed

Presented By

Prof. Tatiana Korotaeva, Nasonova Research Institute of Rheumatology, Russia

Conference

EULAR 2021

2 August, 2021 18:13

Psoriasis and hidradenitis suppurativa during COVID-19: keep calm and carry on

Presented By

Prof. April W. Armstrong, University of Southern California, USA

Conference

AAD VMX 2021

7 June, 2021 13:32

IL-17 inhibitor effective in axial manifestations of psoriatic arthritis

Trial

Phase 3, MAXIMISE

Conference

AAD VMX 2021

7 June, 2021 13:00

Upadacitinib shows benefit in psoriatic arthritis, higher dose bests adalimumab

Journal

The New England Journal of Medicine

31 March, 2021 23:00

COVID-19 in patients with rheumatic disease: most report mild disease

Presented By

Dr Akhil Sood, University of Texas Medical Branch, USA

Conference

ACR 2020

18 January, 2021 10:57

Promising novel treatment option for psoriatic arthritis

Presented By

Prof. Philip J. Mease, University of Washington, USA

Conference

ACR 2020

18 January, 2021 10:51

Ixekizumab shows sustained improvements in pain and fatigue at 3 years

Presented By

Prof. Ana-Maria Orbai, Johns Hopkins University School of Medicine, USA

Trial

SPIRIT-P2

Conference

EULAR 2020

14 August, 2020 14:15

Adalimumab added to methotrexate yields better results in PsA than methotrexate escalatio

Presented By

Dr Laura Coates, Oxford University, United Kingdom

Trial

Phase 4, CONTROL

Conference

EULAR 2020

14 August, 2020 14:09

Upadacitinib provides fast onset of improvement in psoriatic arthritis

Presented By

Prof. Iain McInnes, University of Glasgow, Scotland

Trial

SELECT-PsA-1

Conference

EULAR 2020

14 August, 2020 14:02

ECLIPSE trial: skin clearance independent of PsA status at baseline

Presented By

Prof. Kristian Reich

Trial

Phase 3, ECLIPSE

Conference

AAD 2020

7 August, 2020 13:12

Lowest risk of infection after therapy with an IL-12/IL-23 blocker

Presented By

Dr Yinzhu Jin, Brigham and Women´s Hospital and Harvard Medical School, Boston, USA

Trial

Cohort study

Conference

ACR 2019

4 February, 2020 23:42

Psoriasis onset determines sequence of symptoms

Presented By

Prof. Umut Kalyoncu, Hacettepe University, Turkey

Conference

ACR 2019

4 February, 2020 23:07

Higher psychiatric comorbidity in women with PsA

Presented By

Prof. Mehmet Duruöz, Marmara University Hospital, Turkey

Conference

ACR 2019

4 February, 2020 22:50

Selective IL-23 blocker shows remarkable efficacy in patients with psoriatic arthritis

Presented By

Prof. Atul Deodhar, Oregon Health & Science University, USA

Trial

Phase 3, DISCOVER

Conference

ACR 2019

4 February, 2020 19:53

Efficacy and safety of ixekizumab versus adalimumab in patients with PsA

Presented By

Dr Roy Fleischmann, University of Texas Southwestern Medical Center, Dallas, USA

Conference

EULAR 2019

4 September, 2019 11:20

Efficacy and safety of bimekizumab in patients with active PsA

Presented By

Dr Christopher Ritchlin, University of Rochester Medical Centre, USA

Trial

Phase 2, BE ACTIVE

Conference

EULAR 2019

4 September, 2019 11:10

Filgotinib is efficacious and safe in PsA

Presented By

Prof. Philip Mease, Swedish Medical Center and University of Washington, Seattle, USA

Trial

Phase 2, EQUATOR

Conference

EULAR 2019

4 September, 2019 11:00

Ixekizumab improves signs and symptoms in TNFi-naïve PsA patients

Presented By

Dr Amanda Gellett, Eli Lilly, USA

Trial

Phase 3, SPIRIT-P2

Conference

EULAR 2019

4 September, 2019 10:50

Etanercept and methotrexate as first-line treatment in PsA

Presented By

Prof. Philip Mease, University of Washington, USA

Trial

Phase 3, SEAM-PsA

Conference

EULAR 2019

4 September, 2019 10:40

Unacceptable pain is common in patients with psoriatic arthritis

Presented By

Dr Tor Olofsson, Lund University, Sweden

Conference

EULAR 2019

4 September, 2019 10:33

NSAIDs consumption is linked to patient-assessed disease activity and decreases with use of TNF inhibitors

Presented By

Dr Olafur Palsson, University Hospital Reykjavik, Iceland

Trial

ICEBIO database

Conference

EULAR 2019

4 September, 2019 10:11

Advances in target-oriented therapy: psoriatic arthritis

Presented By

Prof. Wolf-Henning Boehncke, University of Geneva, Switzerland

Trial

ECLIPSA, TICOPA

Conference

10:14:19pm> hello nurse from conference

21 June, 2019 23:48

Plaque psoriasis – Efficacy of guselkumab

Trial

Phase 3, VOYAGE 1, VOYAGE 2

Conference

AAD 2019

19 April, 2019 20:06